[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495504":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":46,"responsibleParty":64,"collaborators":67,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":81,"sex":87,"minAge":88,"maxAge":32,"enrollmentInfo":89,"targetDuration":32,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":102,"overallStatus":49,"whyStopped":32,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"University Hospital, Akershus","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Arm","ACTIVE_COMPARATOR","The patients randomised into this arm of the trial will receive 500 mg Nicotinamide Riboside b.i.d. The duration of blinded therapy will depend on the duration of anthracycline therapy, and will for some patients last for 3 months, others for 6 months.",[13],"Dietary Supplement: Nicotinamide Riboside",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Control Arm","PLACEBO_COMPARATOR","The patients randomised into this arm of the trial will receive a matching placebo b.i.d. The duration of treatment is equivalent to the description in the treatment arm.",[19],"Dietary Supplement: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","Nicotinamide Riboside","Nicotinamide Riboside 500mg b.i.d as long as the patient is receiving anthracycline therapy",[9],[27],"Niagen (serial number 85932490, registration number 4606519)",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo","Matching placebo b.i.d as long as the patient is receiving anthracycline therapy",[15],null,[34],{"name":35,"affiliation":5,"role":36},"Torbjørn Omland, MD, PhD","PRINCIPAL_INVESTIGATOR",[38,42],{"name":35,"role":39,"phone":40,"phoneExt":32,"email":41},"CONTACT","+47 40107050","torbjorn.omland@medisin.uio.no",{"name":43,"role":39,"phone":44,"phoneExt":32,"email":45},"Victoria Vinje, MD","+47 92033665","victoria.vinje@ahus.no",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":32,"geoPoint":32,"contacts":55},"Akershus University Hospital","RECRUITING","Lørenskog","Akershus","1478","Norway","NO",[56,57,58,59,62],{"name":35,"role":39,"phone":40,"phoneExt":32,"email":41},{"name":43,"role":39,"phone":44,"phoneExt":32,"email":45},{"name":35,"role":36,"phone":32,"phoneExt":32,"email":32},{"name":60,"role":61,"phone":32,"phoneExt":32,"email":32},"Jürgen Geisler, MD, PhD","SUB_INVESTIGATOR",{"name":63,"role":61,"phone":32,"phoneExt":32,"email":32},"Evandro F Fang, PhD",{"type":36,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"Torbjorn Omland","Professor",[68,71,73,76],{"name":69,"class":70},"ChromaDex, Inc.","INDUSTRY",{"name":72,"class":6},"Norwegian Cancer Society",{"name":74,"class":75},"Norwegian Breast Cancer Association","UNKNOWN",{"name":77,"class":78},"Helse Sor-Ost","OTHER_GOV","100495504","phase-2-nicotinamide-riboside-and-prevention-of-cancer-therapy-related-cardiac-dysfunction-in-breast-cancer-patients-100495504",false,"NCT05732051","Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients","Effect of Nicotinamide Riboside on Myocardial and Skeletal Muscle Injury and Function in Patients With Metastatic Breast Cancer Receiving Anthracyclines","NARNIA","Inclusion Criteria:\n\n* Women with metastatic breast cancer (stage IV breast cancer) scheduled for anthracycline-containing chemotherapy\n* Eastern Cooperative Oncology Group performance status 0-2\n\nExclusion Criteria\n\n* Age \\\u003C18 years\n* Acute myocardial infarction within the last three months\n* Participation in another pharmaceutical clinical trial of an investigational medicinal product (IMP) less than 4 weeks prior to inclusion or use of other investigational drugs within 5 half-lives of enrollment, whichever is longer\n* Conditions that would affect the participants to comply with the study protocol as psychiatric or mental disorders, alcohol abuse or other substance abuse, suspected poor drug compliance, language barriers\n* Life expectancy \\\u003C 6 months\n* Known allergy to any of the components in the Nicotinamide Riboside (Niagen®) tablet\n* Contraindications or inability to undergo CMR examination","FEMALE","18 Years",{"count":90,"type":91},60,"ESTIMATED","INTERVENTIONAL",[94],"PHASE2","Breast cancer is the most common form of cancer in women. Modern breast cancer treatments have led to increased survival, but at the same time, increased risk for cardiotoxicity and development of heart failure. In this study, the investigators want to evaluate whether nicotinamide riboside can prevent cancer-related cardiac dysfunction in metastatic breast cancer patients scheduled for anthracycline therapy. Further, the investigators will evaluate change in signs of skeletal muscle injury and functional capacity.",[97,98,99,100,101],"Breast Cancer","Metastatic Breast Cancer","Cancer Therapy-Related Cardiac Dysfunction","Cardiotoxicity","Heart Failure",[97,103,104,105,106,107,108,109,100,99],"Anthracyclines","Niagen","Nicotinamide riboside","Nicotinamide adenine dinucleotide","Reactive oxygen species","Cardiac Dysfunction","Cardio-oncology","2023-03-16",{"date":112,"type":113},"2023-03-17","ACTUAL",{"date":110,"type":113},{"date":116,"type":91},"2035-09-30",{"name":5,"class":6},1]